Since Americans started importing medications for personal use in larger numbers at the beginning of the last decade, the Pharmaceutical Researchers and Manufacturers of America (PhRMA), Big Pharma, has engaged in media and government relations scare tactics to try and stop them. Apparently, when it comes to foreign versions of the new FDA-Approved Emflaza, which treats Duchenne Muscular Dystrophy, one board member of PhRMA supports importation!
Last week, I wrote about the decision of drug company Marathon Pharmaceuticals to postpone selling Emflaza over pricing concerns and how the issue shines a bright light on the benefits of personal drug importation. To summarize: some folks are outraged because Emflaza (deflazacort) was launched at a price of $89,000 for a one year supply. This seems insane when foreign versions of deflazacort, which cost 1% that amount (less than $1000), are already imported for personal use.
PhRMA is trying to distance itself from Marathon, just like it did with Martin Shkreli, former CEO of Turning Pharmaceuticals, when the price of Daraprim jumped from $13.50 to $750 a pill overnight. The CEO of Marathon, Jeff Aronin, however, sits on PhRMA’s Board of Directors! Last week, John Carroll of Endpoints News predicted last week that Aronin might be dropped. As of today, he’s still there.
Mr. Aronin wrote a letter to the Duchenne community that fully acknowledged American kids were already being treated with an unapproved foreign version of deflazacort. In his words: “As we all know, deflazacort was being used without FDA approval — and without ever having been approved anywhere in the world for Duchenne — by a very small group of patients (roughly 7 to 9 percent) in the Duchenne community who imported it from overseas.”
But does he support it? I mean, after all, the “score” for Marathon is that once it’s available for sale in the U.S., it will be purchased here. At least for the time being, this PhRMA board member does support it and seems to have no concern whatsoever whether the foreign version is safe and effective, not should he, since, like other medications, it was approved for safety and efficacy elsewhere. In noting that Marathon will “pause our commercialization” of Emflaza,” maintain its Expanded Access Patient Assistance Program, Aronin also state: “Patients currently receiving deflazacort from other sources may continue to have that option.” Damn right.
Is it hypocritical of PhRMA to diss Marathon? After all, brand drug companies jacked prices 130 times the inflation rate in 2015. Forty-five million Americans didn’t fill a prescription in 2016 due to cost. PhRMA will continue its practice of legal bribery and unleash a new, shiny PR campaign about life sciences and innovation — to prevent legislative and regulatory reforms that would lower drug prices. It’s going to take an unpredictable, unexpected populist wave of American anger at drug companies to bring their house down. In the meantime, maybe the people will take a hint from one PhRMA board member and import unapproved and lower cost medications.
Tagged with: aronin, Big Pharma, deflazacort, emflaza, marathon, phrma
Don’t blame poor little Big Pharma
Big Pharma is in the mood to share! A new report commissioned by the Pharmaceutical Researchers and Manufacturers of America (PhRMA), the trade association representing the world’s largest global pharmaceutical companies, seems to assert that the blame for high drug prices should be shared with pharmacy benefit managers, retail pharmacies, wholesalers, and, I think, even hospitals – and more. It appears that PhRMA’s main target is the pharmaceutical benefit managers.
Noting that President Donald Trump recently said drug companies are “getting away with murder” – I view this report as pharma’s attempt to communicate, “hey, prez, we’re not alone here in being greedy.” The report has merit, which I’ll explain below when looking at the dollar numbers. But as far as the American consumer is concerned: murder is murder. Hey, I’m just using the president’s words. Due to the killing made by pharma and friends (because they’re all friends), 10s of millions of Americans are leaving their scripts unfilled because the prices, one way or the other, are out of reach.
The report is called “The Pharmaceutical Supply Chain: Gross Drug Expenditures Realized by Stakeholders.” You can find a summary of it here but this is my take on it. (more…)
Tagged with: phrma, supply chain
Executives from Valeant Pharmaceuticals were lambasted about their pernicious business strategy by members of the Senate Special Committee on Aging at a congressional hearing this past Wednesday. I’m glad the hot spotlight continues to shine on the faces of pharmaceutical company executives for runaway drug prices in America, but let’s not go too far differentiating Valeant from many other bigger pharmaceutical companies. While there are important nefarious nuances to Valeant’s practices, their executives were essentially called out for trying to do what all drug company business executives do: make as much money as they possibly can.
Valeant Chief Executive J. Michael Pearson’s contrite response was surreal: “Let me state plainly that it was a mistake to pursue, and in hindsight I regret pursuing, transactions where a central premise was a planned increase in the price of medicines.” I’m sure Mr. Pearson has regrets – even pharma execs feel bad about what they have done – but is the regret really felt for pursuing a business strategy of maximizing drug prices in the U.S. market? As a rational business actor, that’s what his job is as CEO of a publicly-traded company. Isn’t that what all CEO’s of pharmaceutical companies do? Yes, but…
Valeant is viewed as particularly pernicious because its price hikes for critical medications Nitropress, Isuprel, Syprine, and Cupermine, were 310%, 720%, 3,200%, and 6000%, respectively. Even worse these medications are old drugs, not new innovative medications. Those increases make average patented, brand name drug price increases of almost 15% in 2015 look paltry, even when that average exceeded inflation in leaps and bounces, which was under 1%.
Tagged with: Aging Committee, phrma, Susan Collins, Valeant
Continuing our quest to get the truth out and for our elected leaders in Congress to take bold action to protect online access to safe and affordable medication, we’re publishing a section a week of our report called Online Pharmacies, Personal Drug Importation, and Public Health. The Government Accountability Office Report on Internet pharmacies, which we’ve attested contains inaccuracies and is misleading about buying medication online, clearly relied heavily on pharmaceutical industry sources. Here’s how:
Tagged with: Alliance for Safe Online Pharmacies, Eli Lilly, GAO, NABP, National Associations of Boards of Pharmacy, phrma
Some pharmaceutical companies, including many members of the PhRMA, view foreign online pharmacies as a commercial threat because Americans are able to obtain medications at lower prices leading to lower profits. The U.S. pharmacy industry views non-U.S. online pharmacies as unfair competition because the latter can charge lower prices. Many of the groups identified by GAO as stakeholders are drug companies and U.S. pharmacies or groups that they fund, including the following groups:
- Alliance for Safe Online Pharmacies
- International AntiCounterfeiting Coalition
- National Association of Boards of Pharmacy Pharmacies
- National Association of Chain Drug Stores
- National Community Pharmacists Association
- Partnership for Safe Medicines
- Pharmaceutical Security Institute
Of the 35 stakeholder groups identified by GAO, at least 33% (13) are pharmaceutical companies or groups that receive funding by pharmaceutical companies or U.S. pharmacies. Another stakeholder is the Center for Safe Internet Pharmacies (CSIP), as are eight of its member companies. CSIP is a private consortium of businesses formed in response to pressure by the White House Office of the Intellectual Property Enforcement Coordinator, which mostly operates as another voice and information clearinghouse for the other stakeholders listed. Three associations representing U.S. pharmacy boards and pharmacies are listed above.
Drug Companies Front and Center at PSM Interchange Conference
Two weeks ago I brought you some highlights of the PhRMA-led Partnership for Safe Medicines (PSM) Interchange propaganda show, which was held on September 18th. Look over to the left. See that picture. Those logos of big pharmaceutical companies make it abundantly clear who is pushing the distorted message of PSM about personal drug importation and online pharmacies.
I’m not joking about the word “propaganda” applied to the PSM event. The online Merriam Webster dictionary provides the following definition for that word: “ideas or statements that are often false or exaggerated and that are spread in order to help a cause, a political leader, a government, etc.” In this case, as I see it, the “cause” of PSM is the commercial agenda of the pharmaceutical and U.S. pharmacy industries cynically couched behind terms of patient safety. A central message of PSM is that Americans are risking their lives buying medication online from other countries and that there is no way to do so safely. Those are false and exaggerated messages that are potentially leading lawmakers and regulators to overreact and scare Americans from a potential lifeline of affordable prescription drugs. Evidence shows that this has been PhRMA’s communications strategy for more than a decade. (more…)
Tagged with: Counterfeit Drugs, daniel burke, FDA, Interchnage, laganga, Mississippi AG hood, OCI, Partnership for Safe Medicines, phrma, PSM